DNA donaco international limited

Ann: Market Update, page-17

  1. 7,855 Posts.
    lightbulb Created with Sketch. 2479
    I was continuing on from your assumptions to look at the PE. I personally am assuming they can match the FY17 Star EBITDA so, USD61m plus 10% growth at Aristo so, USD11.88m.
    Without the management fee EBITDA will be 71.88m USD

    Translating to AUD90.27m

    AUD 51.45m NPAT at 57% of EBITDA (I think this % will rise as interest payments decrease so this is conservative)
    = .061c EPS FY18

    I think that is fair though, my bull case is AUD100m EBITDA as I have posted in another thread. Works out at .068c EPS so not far off your 7c assumption.

    In terms of FY16, there was a non-cash valuation uplift, on the Star Vegas, of AUD55.2m which was treated as profit. This inflated the NPAT to AUD77.2m for the full year.

    The ACTUAL cash earnings in FY16 was AUD22.9m

    AUD22.9/ 831.2m shares on issue = .0275c CASH EPS

    Share price at close on day of results (30/8/2016) .46c

    .46/.0275 = 16.72 Trailing PE
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
4.3¢
Change
0.000(0.00%)
Mkt cap ! $53.12M
Open High Low Value Volume
4.3¢ 4.3¢ 4.3¢ $17.57K 408.8K

Buyers (Bids)

No. Vol. Price($)
1 63565 4.3¢
 

Sellers (Offers)

Price($) Vol. No.
4.4¢ 2773999 7
View Market Depth
Last trade - 13.59pm 21/07/2025 (20 minute delay) ?
DNA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.